肿瘤药学2025，Vol.15Issue(4)：455-461,7.DOI:10.3969/j.issn.2095-1264.2025.04.03
新型抗体偶联药物引领HER2低表达乳腺癌诊疗变革
Novel antibody-drug conjugates lead the transformation in the diagnosis and treatment of breast cancer with low HER2 expression
摘要
Abstract
Novel antibody-drug conjugates are profoundly changing treatment strategies and concepts of disease classi-fication in breast cancer.Among these,breast cancer with low HER2 expression historically had a poor prognosis due to the lack of effective targeted therapies.Antibody-drug conjugates,represented by trastuzumab deruxtecan,have significantly improved survival outcomes in patients with HER2-low breast cancer across multiple key clinical studies,prompting up-dates in treatment guidelines and expansion of indications.This article systematically reviews the clinicopathological char-acteristics and heterogeneity-related challenges of HER2-low breast cancer,with a focus on the clinical applications and mechanisms of action of new antibody-drug conjugates.It also highlights current diagnostic and therapeutic limitations and suggests in future research directions,thereby providing a theoretical basis for more precise patient stratification and treat-ment.关键词
乳腺癌/新型抗体偶联药物/人类表皮生长因子受体2低表达/分子分型/综述Key words
Breast cancer/Novel antibody-drug conjugate/Low expression of human epidermal growth factor receptor 2/Molecular classification/Review分类
医药卫生引用本文复制引用
刘炜,张杨秋蓉,李莉,曹俊宇,陈锡华,杨昆宪..新型抗体偶联药物引领HER2低表达乳腺癌诊疗变革[J].肿瘤药学,2025,15(4):455-461,7.基金项目
国家自然科学基金青年项目(82002812) （82002812）
昆明医科大学应用基础研究联合专项(202101AY070001-239). （202101AY070001-239）
